Lv1
92 积分 2022-01-04 加入
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
19天前
已完结
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial
24天前
已完结
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
30天前
已完结
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
1个月前
已完结
Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial
1个月前
已完结
Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial
1个月前
已完结
Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma
1个月前
已完结
Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies
1个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
1个月前
已完结
Intratumoural vaccination via checkpoint degradation-coupled antigen presentation
1个月前
已完结
皖公网安备34019202002308
